
-
France says EU to target US online services after Trump tariffs
-
Tsunoda vows to bring 'something different' after Red Bull promotion
-
Verstappen not happy with Tsunoda-Lawson Red Bull swap
-
Experts accuse 54 top Nicaragua officials of grave abuses
-
Remains of 30th victim of Los Angeles fires found
-
EU to target US online services after Trump tariffs: France
-
How Trump's 'liberation day' tariffs will impact China
-
Malaysia suspends search for long-missing flight MH370
-
Search for long-missing flight MH370 suspended: Malaysia minister
-
Europe hits out at Trump tariffs, keeps door open for talks
-
Myanmar's junta chief to head to Bangkok summit as quake toll surpasses 3,000
-
Lawson vows to prove he belongs in F1 after shock of Red Bull axing
-
Australia sweats through hottest 12 months on record: official data
-
Livestock theft is central to jihadist economy in west Africa
-
South African artist champions hyenas in 'eco-queer' quest
-
Danish PM in 'unity' Greenland visit amid US takeover threats
-
Taiwan says US tariffs 'highly unreasonable'
-
Lawson says ruthless Red Bull axing was 'tough to hear'
-
Heat humble Celtics for sixth straight win, Thunder roll on
-
Trump escalates trade war with sweeping global tariffs
-
Japan says US tariffs 'extremely regrettable', may break WTO rules
-
South Koreans anxious, angry as court to rule on impeached president
-
Juve at in-form Roma with Champions League in the balance
-
Injuries put undermanned Bayern's title bid to the test
-
Ovechkin scores 892nd goal -- three away from Gretzky's NHL record
-
Australian former rugby star Petaia signs for NFL's Chargers
-
China says opposes new US tariffs, vows 'countermeasures'
-
Athletics world watching as 'Grand Slam Track' prepares for launch
-
Heat humble Celtics for sixth straight win, Cavs top Knicks
-
Quake-hit Myanmar's junta chief to head to Bangkok summit
-
New Spielberg, Nolan films teased at CinemaCon
-
Shaken NATO allies to meet Trump's top diplomat
-
Israel's Netanyahu arrives in Hungary, defying ICC warrant
-
Shiny and deadly, unexploded munitions a threat to Gaza children
-
Stocks tank, havens rally as Trump tariffs fan trade war
-
Altomare hangs on to tie defending champ Korda at LPGA Match Play
-
Paraguay gold rush leaves tea producers bitter
-
Health concerns swirl as Bolivian city drowns in rubbish
-
Syria says deadly Israeli strikes a 'blatant violation'
-
Financial markets tumble after Trump tariff announcement
-
Starbucks faces new hot spill lawsuits weeks after $50mn ruling
-
Europe riled, but plans cool-headed response to Trump's tariffs
-
'Shenmue' voted most influential video game ever in UK poll
-
New coal capacity hit 20-year low in 2024: report
-
Revealed: Why monkeys are better at yodelling than humans
-
Hemogenyx Pharmaceuticals PLC Announces FDA Annual Report
-
Pantheon Resources PLC Announces Participation in Upcoming Investor Conferences
-
Key details on Trump's market-shaking tariffs
-
'A little tough love': Top quotes from Trump tariff talk
-
US business groups voice dismay at Trump's new tariffs

US drugmaker Eli Lilly says slashing insulin prices
US pharmaceutical giant Eli Lilly announced Wednesday it would cut the cost of its insulin by 70 percent, with President Joe Biden calling on others to follow suit to tackle soaring drug prices.
Manufacturers have ratcheted up insulin prices in recent years, hitting millions of Americans living with diabetes -- and drawing sharp political criticism.
"Insulin costs less than $10 to make, but Americans are sometimes forced to pay over $300 for it. It's flat wrong," said Biden, hailing Eli Lilly's price cut as "huge news."
"It's time for other manufacturers to follow," he added.
Indianapolis-based Lilly announced a series of steps to rein in prices of the life-saving drug, such as capping out-of-pocket costs at $35 per month for people with insurance.
"Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system," the drugmaker said in a statement.
While the $35 cap takes effect immediately, other measures will be implemented in the course of 2023.
A centerpiece is the 70 percent price drop in Humalog, Lilly's most commonly prescribed insulin.
The incidence of diabetes in the United States in adults has doubled over the last 20 years, afflicting 37.3 million people, according to the US Centers for Disease Control and Prevention.
Insulin prices have soared in the US, costing over eight times more than in 32 comparable high-income countries, a 2020 Rand Corporation study found.
The unaffordability of insulin -- particularly to uninsured Americans -- has become a rallying cry for pharmaceutical industry critics.
- Self-rationing insulin -
The cost of a five-pack of Humalog is currently $530.40, although the out-of-pocket price to a user varies depending on one's insurance plan. An average monthly use varies by user, Eli Lilly says on its website.
Drug pricing in the United States is affected not only by the cost of producing and distributing the pharmaceutical, but also other players such as insurers and pharmacy benefit management companies.
Critics such as progressive Senator Bernie Sanders have blasted the industry as emblematic of "unacceptable corporate greed."
"At a time when Eli Lilly made over $7 billion in profits last year, public pressure forced them to reduce the price of insulin by 70%," Sanders said Wednesday after the price-cut announcement.
"Sanofi and Novo Nordisk must do the same," he added, referring to two other companies which along with Lilly dominate the insulin market.
A survey by nonprofit T1International showed that one in four respondents living with diabetes reported rationing their insulin because of the financial strain.
The Inflation Reduction Act, signed into law last year by Biden, capped insulin prices for Medicare recipients at $35 per month, but people with private insurance or without insurance were left out.
Biden, in his State of the Union Address, called on lawmakers to rein in "Big Pharma" and "finish the job this time" by instituting a national cap on insulin.
In the company's statement, Eli Lilly Chief Executive David Ricks called on rival producers to join the effort.
"We know that 7 out of 10 Americans don't use Lilly insulin. We are calling on policymakers, employers and others to join us in making insulin more affordable," said Ricks.
"While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change."
The company's statement referred uninsured consumers to an insulin affordability website, saying they could "receive Lilly insulins for $35 per month."
P.Stevenson--AMWN